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DOI: 10.1111/bcp.13958L E T T E R TO TH E ED I TORDifferences in CYP3A genotypes of a liver transplant recipient
and the donor liver graft and adjustment of tacrolimus doseTacrolimus (Tac) is well established as main immunosuppres-
sant in most immunosuppressive regimens in solid organ trans-
plantation. Due to the narrow therapeutic window, pre dose
Tac levels (C0) are monitored in all patients receiving Tac to
reach optimal therapeutic levels. Tac is metabolized in the liver
and intestine by the cytochrome P450 3A (CYP3A) isoforms
CYP3A4 and CYP3A5. We present a case of an African Ameri-
can woman who underwent a liver transplantation in which
adequate Tac levels were difficult to accomplish due to differ-
ences in cytochrome P450 3A4/5 (CYP3A4/5) polymorphisms
of the transplant recipient and the donor liver graft. This case
report highlights that genotyping the liver transplant recipient
and the donor liver graft might provide data which could be
used to predict the tacrolimus metabolism post transplantation.
After solid organ transplantation, tacrolimus is used to prevent
allograft rejection in the long term. Tac is known for its narrow
therapeutic window with large interpatient pharmacokinetic variabil-
ity where underexposure poses a risk to allograft rejection and over-
exposure might increase the incidence of infections and toxicity.1
Tac is metabolized in the liver and intestine by the cytochrome
P450 3A (CYP3A) isoforms CYP3A4 and CYP3A5. Patients carrying
at least one CYP3A5*1 variant allele are considered to be CYP3A5
expressers; these patients have low Tac exposure due to rapid
metabolism of Tac. Patients carrying a CYP3A5*3, CYP3A5*6, or
CYP3A5*7 variant allele have nonfunctional CYP3A5 protein and
are considered to be CYP3A5 non‐expressers. Approximately 55%
of African Americans are carriers of the CYP3A5*1 variant allele.2
CYP3A5 expressers require a Tac dose that is approximately 1.5‐
to 2‐fold higher than non‐expressers to reach equivalent Tac expo-
sure.3 Also, the effect of the drug‐drug interactions between Tac
and CYP3A4/CYP3A5 inducers/inhibitors will be enhanced in
CYP3A5 expressers. Monostory et al found an association between
Tac blood levels in liver transplant recipients and donors' CYP3A5
genotype as well as CYP3A4 expression.
We present a case in which the genotype of the donor liver graft
had a significantly less important effect on Tac pharmacokinetics than- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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1852 wileyonlinelibrary.com/journal/bcpthe genotype of the liver transplant recipient during the first month
post transplantation. A 33‐year‐old African American woman, known
to have sickle cell disease, G6PD deficiency, osteoporosis, and colitis
ulcerosa, received an uncomplicated donation after brain death
(DBD) liver transplantation (LTx) because of a cirrhosis and recurrent
cholangitis due to primary sclerosing cholangitis (PSC). Tac was initially
started at day 5 at a lower dose (2 mg twice daily; 62 kg) because of a
postoperative pulmonary infection.
Target Tac whole blood levels were set at 6‐10 μg/L in the
first month after LTx followed by target Tac whole blood levels of 4‐
8 μg/L from the second month onwards.4 Tac levels were measured
by ultra‐high‐performance liquid chromatography‐electrospray
ionization‐tandem mass spectrometry (UHPL‐MS/MS XevoTQ, Water
Chromatography, BV, USA). After several dose adjustments shown in
Figure 1, the Tac trough level was still inadequate (4.5 μg/L) at day
16, which resulted in an additional dose increase to 24 mg twice daily.
A daily dose of 48 mg correlates with a dose of 0.8 mg/kg/day in our
patient, which may potentially lead to toxic peak levels. To prevent
potentially toxic peak levels, the dosing interval of Tac was shortened
to 16 mg three times daily at day 17. Because of the lower doses per
administration, lower peak levels will be reached. Subsequently, Tac
trough levels will be higher due to a shorter elimination time of Tac.
The AUC is the best marker for total drug exposure and could be cal-
culated based on a limited number of blood samples strategy using
Bayesian estimation. At day 18, blood samples were drawn 30 minutes
before the next dose and 1, 2, and 4 hours after Tac dosing; the
measured concentrations were 12.3, 11.6, 12.8, and 28.9 μg/L respec-
tively. Note that at day 18, a single dose of fluconazole 400 mg was
administered because of its ability to inhibit CYP3A enzymes. The
AUC0–8 was 240 μg*u/L, calculated with MW/Pharm, and the trough
level was 12.3 μg/L. It should be taken into account that our patient
was on a three times daily dosing regimen, which reflects an AUC0–8.
Our calculated AUC0–24 (720 μg*u/L) was higher than the target
AUC0–24 (400‐420 μg*u/L).
5 Guy‐Viterbo et al6 showed that fluconazole
significantly increased Tac trough levels from day 2 to 30 post transplan-
tation, especially in CYP3A5 expresser recipients. The combination of
single‐dose fluconazole administration and shortening of the dosing
interval may have positively influenced theTac exposure. However, our
patient did not have a fungal infection, so multiple daily dosing of- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
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FIGURE 1 Tac trough levels in μg/L (blue
line) and daily doses in mg (green bar) versus
days after LTx
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appropriate. As biopsies of the liver graft were already taken, we geno-
typed both our patient and the donor liver graft after informed consent
was obtained. Genomic DNA was extracted from whole blood of the
patient and from the donor liver biopsy using the Total Nucleic Acid
DNA isolation kit on a MagnaPure Compac (Roche Diagnostics, Mann-
heim, Germany). Genotyping of the CYP3A4*22 and CYP3A5*3, *6,
and *7 SNPs was performed using the TaqMan® (ThermoFisher Scien-
tific, CA, USA) genotyping assays according tomanufacturer instructions.
The results suggests that our patient is a CYP3A5 expresser (CYP3A5 *1/
*1) with a normal CYP3A4 enzyme activity (CYP3A4 *1/*1B) explaining
low Tac exposure. However, the results of the donor liver graft showed
that the donor liver has a reduced CYP3A4 activity (CYP3A4 *1/*22)
and nonfunctional CYP3A5 enzymes (CYP3A5 *3/*3). In theory, this
genotype would cause higher Tac exposures in patients.6
Several studies showed that, in adult liver transplant patients,
CYP3A5 expression in liver donor grafts and in transplant recipients
resulted in higher Tac daily doses to achieve adequateTac exposure. Ini-
tially, the recipient CYP3A activity seems to have the greatest influence
on Tac pharmacokinetics, but this changes over time when the donor
CYP3A activity becomes more important.7-10 In the case of our patient,
the metabolism of Tac in the intestine also had a more important effect
on Tac pharmacokinetics than the metabolism of Tac in the donor liver
in the first month after transplantation. However, these aforementioned
studies mostly describe the influence of the transplant recipients' and
donor liver grafts' CYP3A5 status on Tac metabolism. In this case, the
donor liver graft was a CYP3A5 non‐expresser but had a reduced
CYP3A4 activity (CYP3A4 *1/*22), which have not yet been studied in
combination with a transplant recipient CYP3A5 expresser. Therefore,
we could hypothesize that the clearance of Tac by the donor liver is
reduced because of its decrease in CYP3A4 expression and therefore
more Tac is metabolized in the intestine, resulting in a substantially
increased clearance because of its CYP3A5 expression. At day 31, our
patient achieved adequate Tac levels (6.0 μg/L) with a dosing regimen
of 10 mgTac three times a day. If we had genotyped this patient before
transplantation, we would have started with a dose of 0.3 mg/kg/day.
This would have resulted in higher pre dose concentrations early aftertransplantation, however not as high as needed to reach the therapeutic
window.
In conclusion, this case shows the difficulties of adjusting dosing
regimens to obtain adequateTac levels in patients with CYP3A genetic
polymorphisms.
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